In this way, gliflozins help to treat anemia in CKD directly by removing EPO-inhibiting factors (proinflammatory substances) and indirectly by stimulating EPO production through HIF-2α and SIRT-1, as well as their impact on iron store mobilization. Here, EPO is linked to anemia (phenotype).